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Summary 
 
 
Although outcome data for individuals with cystic fibrosis (CF) have shown consistent 
improvements throughout the twentieth century, more recent national registry data suggests 
that outcomes have reached a plateau. Median values for nutritional outcomes in CF 
currently cluster around the fiftieth centile for the normal population. These data suggest that 
up to half of CF patients have sub-optimal body mass index (BMI) which might have a 
significant adverse impact on their respiratory status. BMI might be underestimating the 
extent to which more important lean body mass might also be reduced.  Nutritional decline is 
a particular problem during adolescence and commonly persists into early adult life. Current 
treatment strategies to optimize nutrition include the use of high energy diets, proton pump 
inhibitors and optimal use of enzyme preparations including higher strength preparations to 
decrease pill burden. Whilst these are all of potential benefit, poor adherence to nutritional 
care recommendations is probably the greatest impediment to future health improvement. 
More effective strategies to impact on treatment adherence are needed. 
 
 
 
 
 
Introduction 
 
 
Maintaining good nutritional status is critical to the long-term survival of patients with Cystic 
Fibrosis (CF) and within the CF community much emphasis is placed upon the important 
association between poor nutrition and worsening lung function [1,2]. Analysis of outcome 
data obtained from the UK national registry of successive birth cohorts from the 1960s 
through to the 1990s showed progressive improvements in survival [3] and life table methods 
to predict survival of infants diagnosed at the beginning of the twenty-first century estimated 
that patients might expect to survive to a median age of over forty[4]. 
 
 
 
 
 
 
Port CF data 
 
 
Port CF is the UK National database for CF patients. Outcome data from this registry for 
2007- 2012 is shown in table 1. Although there might have been some incomplete data 
collection in the earlier years, these data suggest that more recently there has been very little 
improvement in clinically relevant outcome parameters pertaining to nutrition and respiratory 
status. New treatments such as Ivacaftor (Kalydeko), a CF potentiator, have been of 
considerable clinical benefit, but only approximately 5% of the UK CF population are 
suitable and it has only been widely available since 2012. Advances in CF care in the 6 years 
before this drug’s release, have largely been confined to improved service delivery of existing 
treatments.  Such developments appear to have had little impact on the outcome measures 
shown, and suggest a need for a change of emphasis in clinical care. 
 
The median BMI in the UK is 22 for adults and just above the 50th centile for children. 
Whilst it might seem encouraging to observe that the overall body mass index (BMI) 
distribution of the CF population approximates to that of the normal UK population, this 
belies the fact that the median BMI decreases during late childhood and persists at a lower 
level into early adult life. This is a critical time for patients and the decline thus far has been 
poorly responsive to recent increases in specialist services and the provision of good 
transition from paediatric to adult care. 
BMI, lean body mass and Lung function 
 
 
There is a clear association between reduction in BMI to below the 50th centile and reduced 
lung function expressed as FEV1% predicted.  This relationship persists in analyses restricted 
to pancreatic insufficient patients who are homozygous for the DeltaF508 genotype, and a 
linear positive relationship between BMI and lung function continues above the 50th centile, 
albeit at a less steep incline [5]. A longitudinal cohort study from Toronto confirms this 
relationship between improved lung function amongst individuals who might be considered 
to be overweight or even obese, but points out that the benefits of a BMI above 25kg/m2 are 
small and need to be balanced against the known long term health risks associated with 
obesity [6]. 
 
 
 
 
 
Many previous reviews have stressed the importance of aggressive nutritional support, 
encouraging a high calorie, high protein, unrestricted diet to promote normal growth [7]. The 
US cystic fibrosis foundation recommends that all CF children should have a BMI above the 
50th centile and all CF adults a BMI > 22 [8]. Current UK outcome data would suggest that 
these nutritional outcomes are not being achieved in almost a half of the UK CF population. 
 
 
 
 
 
Even if a BMI above the 50th centile is achieved for all patients, this might not be enough to 
ensure that nutritional factors are not still adversely impacting on respiratory outcomes.  A 
recent cross sectional study of nutritional parameters from the Children’s hospital of 
Philadelphia, has helped clarify the important relationship between BMI and lean body mass 
(LBM) in CF [9]. Using spine and whole body dual energy X-ray absorptiometry, the group 
were able to estimate LBM and fat mass in their CF patients in comparison to a healthy 
control population. These data were used to determine the extent to which BMI is a proxy 
indicator of lean body mass, the latter being a more important determinant of respiratory 
muscle strength, lung function and overall physical well being. Although BMI was shown to 
be a relatively useful indicator of nutritional status, the study highlighted important sex 
differences in body composition in the CF population compared to normal controls. In 
particular data showed that a low lean body mass index (LBMI) was associated with worse 
lung function in males irrespective of whether their BMI was above or below the 50th centile. 
In females, a lower LBMI was only associated with worse lung function if their BMI was sub-
optimal. Studies such as this suggest the potential value of measurements of LBM as a part of 
routine clinical care, and in particular to detect a reduced LBMI in boys who are achieving 
their target BMI. These data also highlight the need for longitudinal studies to define the 
interventions that are likely to be effective, not just to improve BMI to above the 50th centile, 
but also to achieve improvements in LBMI, irrespective of BMI, to maximise overall health. 
 
This issue is complex, and the relationship between LBM, fat mass and optimal strategies to 
improve nutrition to stabilise lung function are unclear. This has been highlighted in a recent 
adult study where enteral feeds were reported as stabilising lung function as result of 
increased android fat distribution, a known risk factor for diabetes, but with little impact on 
lean body mass [10]. 
 
 
 
 
 
BMI, lean body mass and resting energy expenditure 
 
 
Although port CF data suggests that a decline in BMI tends to predate reduced lung function, 
there is a clearly a complex relationship between nutritional intake, lung infection, and 
metabolic demand. A study of the effect of chronic infection with pseudomonas on resting 
energy expenditure, (REE) expressed as kilo calories per unit of lean body mass, 
demonstrated a 50% increase in REE compared to individuals without chronic infection [11]. 
These findings highlight how the inflammatory burden, and increased work of breathing 
associated with pulmonary sepsis, contributes to a vicious cycle of decreasing muscle mass 
and worsening respiratory status. 
 
 
 
 
 
Proton pump inhibitors 
 
 
Medical interventions to improve nutritional status are largely limited to adjustments of either 
pancreatic enzyme dose or formulation, and the use of acid suppression treatment. The use of 
proton pump inhibitors (PPIs) to raise proximal small bowel pH, and thus optimise enzyme 
efficacy, has increased significantly over recent years. In 2012, 40.5% of the UK CF 
population were prescribed PPIs (table 2). Whilst there is limited evidence that PPIs reduce 
gastric acidity and improve fat absorption, published studies thus far have not determined 
whether their long term use improves nutritional status and/or lung function [12]. This class 
of drugs has the potential for side effects that are worthy of consideration. Studies of the use 
of PPIs in non CF patient groups have shown a dose related risk for community acquired 
pneumonia after short term use [13], and a recent study in CF has raised the possibility of an 
association between the use of esomeprazole and risk of pulmonary exacerbation [14]. Other 
observations that might be of relevance to CF patients is the association between prolonged 
PPI use and increased relative risk of fractures as demonstrated in a UK wide primary care 
based study and corroborated by a large meta-analysis [15, 16]. 
Pancreatic enzymes 
 
 
Eighty-four per cent of the UK CF population are pancreatic insufficient, and the median 
recorded daily lipase dose has remained much the same between 2007-2012 (Table 2). Lipase 
doses are higher amongst those taking higher strength preparations (Figure 1), although in a 
post marketing survey following the introduction of Creon 40,000, the mean daily lipase dose 
was decreased by an average of 11% compared to the doses used at baseline [17]. 
 
 
 
 
 
A recent US study comparing outcomes between different centres, showed a significant 
difference in median enzyme dose between centres in the highest and lowest quartile groups 
for BMI centile [18]. Whilst these findings suggest that using higher enzyme doses might 
improve CF outcomes, the range of doses reported were relatively low compared to those 
used in the UK, and the difference in doses between the centres with the best and the worse 
outcomes were relatively small. Historical concerns about the risks of fibrosing colonopathy 
in relation to excessive enzyme usage are noteworthy, but it would appear that current UK 
practice for enzyme use is not associated with the occurrence of this complication [19] (figure 
1). 
 
 
 
 
 
Non-adherence 
 
 
Pill burden, in relation to the number of capsules that have to be ingested, rather than absolute 
dose of pancreatic enzyme, is potentially of greater relevance to the optimal correction of 
malabsorption in clinical practice. Studies in patients with HIV of treatment related 
determinants of non adherence identified that a high pill burden, of more than 10 pills per 
day, was more predictive of non adherence to anti-retroviral therapy than other risk factors 
including the occurrence of side effects, anxiety, depression, alcohol and substance abuse and 
dosing regimen [20]. A review of studies addressing non-adherence in cystic fibrosis has 
recently been reported [21]. Whilst the researchers noted there were significant limitations in 
our current understanding of the prevalence of non-adherence in CF, the limited data 
available suggested that the lowest levels of adherence were to nutritional aspects of care. 
Such findings emphasize how strategies to address non-adherence are of central importance 
in enabling CF patients to gain optimal benefit from currently available therapies. Addressing 
these unmet needs, with a particular focus on the nutritional requirements of patients below 
the 50th centile for BMI in the first instance, would seem a worthwhile approach towards 
achieving future improvements in clinically relevant outcomes. 
 
 
 
Table 1. CF Registry data 2007-2012 
 
 
 
 
Year 
2007 2008 2009 2010 2011 2012 
Number of reports 4408 6082 7377 7937 8679 8795 
Male n (%) 2375 (53.9) 3239 (53.3) 3916 (53.1) 4217 (53.1) 4621 (53.2) 4621 (52.5) 
Age 18.3 (10.0, 26.7) 18.1 (9.8, 26.6) 17.8 (9.4, 26.9) 17.9 (9.3, 27.8) 18.3 (9.3, 27.8) 18.6 (9.3, 28.2) 
 FEV1 (% of predicted) 72.6 (24.8) 72.0 (24.6) 71.8 (24.4) 71.6 (24.4) 72.4 (24.5) 71.7 (24.7)   
BMI 
Adult (kg/m
2
) 21.7 (16.8, 23.9) 21.7 (19.7, 24.0) 21.7 (19.8, 24) 21.4 (19.5, 23.6) 22.0 (20.0, 24.4) 22.0 (20.0, 24.4) 
 
Child ≤ 17 
 years centile 53.3 (26.9, 75.4) 51.7 (26.6, 74.3) 51.1 (25.9, 75.5) 52.2 (28.5, 75.0) 53.8 (28.0, 76.7) 52.7 (28.1, 75.5)   
 
 
 
 
 
 
All continuous data except FEV1 were skewed so are expressed as medians (interquartile ranges). FEV1 was approximately normally distributed and is 
expressed as mean, (standard deviation). 
 
Table 2. Pancreatin and acid suppression therapy 
 
 
 
 
Year 
 2007 2008 2009 2010 2011 2012 
Proton pump inhibitor n (%) 970 (22.0) 1653 (27.2) 2267 (30.7) 2776 (35.0) 3326 (38.3) 3560 (40.5) 
H2 antagonist n (%) 169 (3.8) 261 (4.3) 331 (4.5) 360 (4.5) 448 (5.2) 474 (5.4) 
Antacid n (%) 26 (0.6) 72 (1.2) 74 (1.0) 100 (1.3) 102 (1.2) 130 (1.5) 
Pancreatic enzymes n (%) 3145 (71.3) 4835 (79.5) 5975 (81.0) 6672 (84.1) 7328 (84.4) 7389 (84.0) 
≥10,000 units lipase/kg/day n 
 (%)   
 
626 (20.8)   
 
973 (21.1)   
 
1239 (21.9)   
 
1507 (23.3)   
 
1559 (22.3)   
 
1464 (21.2)   
Total lipase/kg/day median 
  (IQR)   
6632 
(4184, 9404)   
6832 
(4314, 9469)   
7026 
(4474, 9615)   
7022 
(4521, 9746)   
6937 
(4395, 9615)   
6842 
(4371, 9459)   
 
 
Percentages are percentage of all patients contributing data except lipase dose where those not on lipase replacement therapy are excluded from analysis. 
Lipase dose data are skewed so are expressed as medians (interquartile ranges). 
 
Figure 1. Relationship between pancreatic enzyme dose (lipase units/kg/day) and age enzyme preparation (2012 data, n=7,164)* 
 
 
 
 
 
 
Footer: * data not shown for 175 patients (2.0%) taking multiple preparations and 50 patients (0.6%) taking alternative enzyme preparations not displayed 
above. 
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